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This work represents the first evaluation of the effects of water extract of C. nuda (WE-CN), an edible mushroom, on murine bone
marrow-derived dendritic cells (BMDCs) and the potential pathway through which the effects are mediated. Our experimental
results show thatWE-CN could induce phenotypic maturation of DCs, as shown by the increased expression ofMHC and costimu-
latorymolecules. In addition, it also induced the proinflammatory cytokines expression onDCs and enhanced both the proliferation
and IFN-𝛾 secretion of allogenic T cells. Therefore, since WE-CN did not induce maturation of DCs generated from mice with
mutated TLR-4 or TLR-2, suggesting that TLR4 andTLR2might function asmembrane receptors forWE-CN.Moreover, themech-
anism of action ofWE-CNmay be mediated by increased phosphorylation of ERK, p38, and JNKmitogen-activated protein kinase
(MAPK) and increased NF-𝜅B p65 activity, which are important signaling molecules downstream of TLR-4 and TLR-2. Finally,
coimmunization of mice withWE-CN and a HER-2/neu DNA vaccine induced a HER-2/neu-specificTh1 response that resulted in
significant inhibition ofHER-2/neu overexpressingmouse bladder tumor (MBT-2) growth.These data suggest thatWE-CN induces
DC maturation through TLR-4 and/or TLR-2 and that WE-CN can be used as an adjuvant in cancer vaccine immunotherapy.
1. Introduction
Dendritic cells (DCs) are professional antigen-presenting
cells (APCs) that play a key role as immune sentinels by
initiating T-cell responses and linking innate and adaptive
immunity [1, 2]. DCs are present at different stages of mat-
uration in the circulation and in nonlymphoid and lymphoid
organs. DCs reside in an immature form in peripheral non-
lymphoid tissues, where they capture and process exogenous
antigens [3]. Once activated, DCs migrate to the T-cell-
dependent areas of secondary lymphoid organs, where they
present antigenic peptides to T lymphocytes and stimulate
na¨ıve T-cell responses through cytokine signals, major his-
tocompatibility complex- (MHC-) presenting Ag peptides
and costimulatory molecules (e.g., CD40 and CD80). As
key regulatory mediators of immune responses, DCs are
being pursued for the development of potent new vaccines
against cancer and infectious diseases [4, 5]. In addition, the
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identification of materials that can modulate DC activation
and function is an emerging field that can develop alongside
DC immunobiology [6]. Natural or synthetic activators
that promote DC activation may potentially be candidate
adjuvants for application in immunotherapy and vaccination.
Growing evidence-based research has suggested benefits
of consumingmushrooms as a functional food or through the
use of extracted bioactive compounds as dietary supplements,
immunomodulators (biological response modifiers), and
adjuvant tumor therapy [7–10]. Numerous compounds have
been isolated from mushrooms and have great potential for
development asmushroomnutraceutical and pharmaceutical
products. Among these compounds, water-soluble polysac-
charides and proteoglycans, proteins, and various consti-
tuents of small molecular mass are considered to have
immunomodulatory potential by regulating several types of
immune cells that function in antitumor or antimicrobial
activities, including dendritic cells, macrophages, cytolytic T
cells, and NK cells [9–12].
Clitocybe nuda (also known as Lepista nuda, commonly
known as blewits) is an edible woodland mushroom found
in Europe, North America, Asia, and Australia [13]. Due
to its special fragrance and delicate texture, C. nuda has
been cultivated in France, Holland, Britain, and Taiwan.
Several bioactive extracts from C. nuda have been found
to exhibit antioxidant and antimicrobial properties [14–18],
but few reports have described medicinal activities or health
benefit in human disorders. To our knowledge, only three
papers have shown that C. nuda extract affects cancer cells in
vitro [19–21]. However, no studies have specifically reported
immunologic effects of C. nuda.
Therefore, to study the effects of C. nuda on immune
response and its potential cellular targets, we investigated
whether C. nuda affects the maturation and functional
properties of murine bone marrow-derived dendritic cells
(BMDCs). Our findings demonstrate for the first time that
water extract Clitocybe nuda (WE-CN) induces the pheno-
typic and functional maturation of BMDCs via ERK1/2, JNK,
and p38 MAPK and the nuclear translocation of the NF-
𝜅B p65 subunit, in part, by the TLR-4 and TLR-2 pathways.
Significantly, WE-CN cotreatment enhanced the therapeutic
efficacy of a HER-2/neu DNA vaccine against HER-2/neu-
overexpressing tumors, suggesting that WE-CN could be
a novel adjuvant and has potential application in cancer
therapy and vaccination.
2. Material and Methods
2.1. Mice and Cell Cultures. Five- to eight-week-old specific
pathogen-free female C57BL/6, C3H/HeN, and C3H/HeJ
(TLR-4 mutant) mice were purchased from the National
Laboratory Animal Center (Taipei, Taiwan). TLR-2 knockout
micewere provided byDr.Chih-PengChang (NCKU,Tainan,
Taiwan). OT-I TCR transgenic mice were purchased from
the Jackson Laboratory (Bar Harbor, ME, USA). OT-II TCR
transgenic mice were provided by Dr. Clifford Lowell (UCSF,
San Francisco, CA, USA). All mice were housed in the barrier
facility at Taichung Veterans General Hospital (Taichung,
Taiwan) in accordance with the Institutional Animal Care
and Use Committee guidelines for animal experimentation,
and all procedures were performed in accordance with the
Institutional Animal Care and Use Committee guidelines for
animal experimentation.
TheMBT-2 murine bladder tumor cell line, derived from
a carcinogen-induced bladder tumor in C3H mice, has been
described and is known to express high levels of p185neu [22].
Mouse DCs were generated from bone marrow as previously
described [23]. Bone marrow (BM) cells were flushed from
the femurs and tibias of C57BL/6 mice, lyzed red blood cells
with ammonium chloride, and then washed with PBS. BM
cells were suspended in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, 100U/mL
penicillin G, 100 𝜇g/mL streptomycin, 2mM L-glutamine,
20 ng/mL recombinant mouse granulocyte-monocyte col-
ony-stimulating factor (Peprotech) and 20 ng/mL recombin-
ant mouse IL-4 (Peprotech), and culturedin 24-well plates (5
×10
5 cells/mL). Freshmediumwas supplied every 2 days, and
nonadherent cells were harvested on day 7 as immature DCs.
2.2. Preparation ofWater Extract C. nuda. The fruiting bodies
of C. nuda strain Tainung No. 1 were cultivated on compost
and harvested by the Taiwan Agricultural Research Institute
Mushroom Laboratory. After oven-drying, 30 g of the dried
mushroom samples were milled and submitted to aqueous
extraction under reflux (40x at 100∘C for 40min). The
aqueous extract was filtered over Whatman no. 1 paper, and
the filtrate was evaporated to a small volume and lyophilized.
The dry extracts were stored frozen at −20∘C until use.
The crude extracts were resolubilized in MilliQ water at 4
different concentrations (12.5, 25, 50, and 100 𝜇g/mL). To
remove endotoxins (lipopolysaccharides or LPS), the sample
preparations were passed through an EndoTrap Blue column
(Hyglos, Bernried, Germany). The level of endotoxin in the
sample preparation was determined by a quantitative, chro-
mogenic QCL-1000 Limulus amoebocyte lysate (LAL) assay
(Cambrex Bio Science Walkersville, Inc., Walkersville, MD,
USA) and was found to be <0.1 ng/mg protein. Furthermore,
to inhibit endotoxin activity, the samples were incubated on
a rotator for 2 hours at 37∘C with 10 𝜇g/mL polymyxin B.
2.3. In Vitro DC Activation. Immature DCs were cultured at
a density of 1 × 106 cells/well in 24-well plates in medium
alone or in the presence of 100 ng/mL LPS (Escherichia coli,
serotype O26:B6 (Sigma St. Louis, MO, USA)), 1 𝜇g/mL
lipoteichoic acid (LTA, LTA; L2515, from Staphylococcus
aureus, SIGMA, St. Louis, MO, USA), or WE-CN (0, 25, 50,
or 100 𝜇g/mL) for 24 hr (or 6 hr for the TNF-alpha ELISA).
The cells were then used for further immunophenotyping, the
cytokine production assay, or the addition of T cells for DC-T
coculture experiments.
2.4. Flow Cytometric Analysis of Surface Markers. After
stimulation, DCs were harvested and stained with FITC-
conjugated mouse CD11c+ or phycoerythrin- (PE-) con-
jugated anti-mouse CD40, anti-mouse CD80, anti-mouse
CD86, anti-mouse MHC class I, anti-mouse MHC class II,
or isotype-matched control mAbs (all from BioLegend, San
Diego, CA, USA) for 45min on ice (1 𝜇g/mL diluted in
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PBS/1.0% FCS (v/v)). After washing with PBS, the fluorescent
intensity was measured with a FACSCalibur flow cytometer
(BD Biosciences), and the data were analyzed using WIN-
MDI software (Scripps, La Jolla, CA, USA). The results are
expressed in terms of the relative mean fluorescence intensity
(MFI) on CD11c+ gated conventional dendritic cells.
2.5. Cellular Morphology Analysis. The morphology of the
DC cells was examined on day 6 and 24 h after LPS or WE-
CN stimulation using a phase contrastmicroscope and digital
photography to record the images.
2.6. Cytokine Detection. To quantify the production of
cytokines and chemokines, supernatants were collected from
immatureDCs propagated in the presence of LPS orWE-CN.
After incubation, cytokines (mTNF-alpha, mIL-6, mIL12p70,
and mIL-4) production by DCs was measured in the super-
natants by sandwich ELISA assays according to the manu-
facturer’s specifications (all from PeproTech, Rocky Hill, NJ,
USA).
2.7. Allogenic Mixed Lymphocyte Reaction. Mouse T cells
were isolated from na¨ıve C57BL/6 mice spleens using Easy-
Sep Mouse T Cell Enrichment Kitseparation, respectively,
according to the manufacturer’s protocol (Stem Cell Tech-
nologies, Grenoble, France). Immature DCs were stimulated
with LPS (100 ng/mL) or CN-WE (100𝜇g/mL) for 24 hr, and
then the cells were harvested, washed, and diluted with the
prepared enriched T cells (2 × 105) in ratios of 1 : 25, 1 : 5, and
1 : 1 (DC : T) in 96-well round-bottom plates (Corning). After
an additional 96 hr of coincubation, cell proliferation was
assessed by adding 1 𝜇Ci of [3H] thymidine (GE Healthcare,
Buckinghamshire, UK) for overnight incubation; quantifi-
cation of incorporated [3H] thymidine was subsequently
performed by liquid scintillation counting on a 𝛽-Counter
(Beckman Instruments, Palo Alto, CA, USA).
2.8. OVA-Specific T-Cell Activation. The protocol for OVA-
specific T-cell activation was modified from our previous
report [23, 24]. Briefly, immature DCs were pulsed with
2𝜇g/mL OVA
257–264 (OVAP1) or OVA323–339 (OVAP2) (syn-
thesized by Echo Chemical Co., Taiwan) in the presence
of LPS or WE-CN (100 𝜇g/mL) for 24 hr. CN was then
washed out, and OVAP
1
-specific CD8+ T cells (2 × 105)
and OVAP
2
-specific CD4+ T cells (2 × 105) were added to
the culture at various DC : T cell ratios (as indicated) in
96-well round-bottom plates. The OVA-specific cells were
positively enriched from the spleens of OT-1 and OT-2 mice
by EasySep Mouse CD8a Positive Selection Kit separation
and EasySep Mouse CD4 Positive Selection Kit separation,
respectively, according to the manufacturer’s protocol (Stem
Cell Technologies, Grenoble, France). After an additional
72 hr of coincubation, T-cell proliferation was measured by
adding 1 𝜇Ci of [3H] thymidine (GE Healthcare, Bucking-
hamshire, UK) for overnight incubation; quantification of
incorporated [3H] thymidine was subsequently performed
by liquid scintillation counting on a 𝛽-Counter (Beckman
Instruments, Palo Alto, CA, USA). In addition, the IFN-
𝛾 cytokine levels in the supernatants from DC-OT-I/OT-
II cultures were determined by a sandwich IFN-𝛾 ELISA
kit (eBioscience San Diego, CA, USA) according to the
manufacturer’s protocol.
2.9. Western Blot Analysis. Immature DCs were stimulated
with 100𝜇g/mLWE-CN, andwhole cell lysates were prepared
at the indicated time points as previously described [23]. The
protease inhibitors leupeptin (Sigma-Aldrich, St. Louis, MO,
USA) and aprotinin (Sigma-Aldrich, St. Louis, MO, USA)
were used at a concentration of at 10𝜇g/mL in all steps.
Protein concentrations were determined using a BCAprotein
assay kit (Pierce Rockford, IL) prior to western blot or other
protein analyses.
For protein detection, protein extracts (40 𝜇g/mL) were
boiled separated on 10% SDS-polyacrylamide gels and elec-
trotransferred to nitrocellulose membranes. The membranes
were blocked for 1 hr with 5% skim milk in TBS + 0.05%
Tween 20. After blocking, the membranes were incubated
overnight with the suggested concentrations of either a
primary antibody against phospho-p38 (no. 9211), p38 (no.
9212), phospho-p42/44 (no. 9101), total p42/44 (no. 9102),
phospho-JNK (no. 4688), and b-Actin (no. 4970) (all pur-
chased from Cell Signaling Technology) or total JNK (SC-
571) (purchased from Santa Cruz Biotechnology, Danvers,
MA, USA). The membranes were washed prior to incuba-
tion with HRP-Conjugated Goat Anti-Mouse IgG or HRP-
Conjugated Goat Anti-Rabbit IgG secondary Abs (Jackson
ImmunoResearch, West Grove, PA, USA). The proteins were
detected by enhanced chemiluminescence (GE Healthcare,
UK) and analyzed using the LAS3000 system (Fujifilm,
Tokyo, Japan). Densitometric analysis was performed with
ImageJ software (National Institute of Health, Bethesda, MD,
USA). Active forms of pErk, p38, and pJNK were normalized
with corresponding total nonphosphorylated forms.
2.10. Preparation of Nuclear Extracts and NF-𝜅B Activity
Assay. Nuclear extracts were prepared using the NE-PER
Nuclear and Cytoplasmic Extraction system (Pierce Rock-
ford, IL, USA) according to the manufacturer’s instructions.
Protein concentrations were determined using a BCAprotein
assay kit (Pierce, Rockford, IL,USA). For each assay, 5mg/mL
of nuclear extracted was used in a TransAM NF-𝜅B p65
ELISA kit (Active Motif, Carlsbad, CA) according to the
manufacturer’s instructions.
2.11. Therapeutic Efficacy in a Mouse Model of Established
MBT-2 Tumors. The MBT-2 tumor model has previously
been described [22]. Briefly, MBT-2 cells (1 × 106) in 0.5mL
of cold PBS were injected subcutaneously (s.c.) into the
flanks of female C3H/HeN mice. Ten days after injection
(when the tumors were palpable), the mice were injected
intramuscularly in the left hind thigh muscles with 100 𝜇g
of the pRC/CMV DNA plasmid (control group), 100𝜇g of
a HER-2/neu DNA vaccine (pRC/CMV vector carrying the
cDNA encoding the extracellular domain of the humanHER-
2/neu) [25] in 100 𝜇L 0.9% NaCl, 100𝜇g of the pRC/CMV
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DNA plasmid mixed with 100 𝜇g WE-CN, or 100 𝜇g of the
HER-2/neu DNA plasmid mixed with 100𝜇g WE-CN. The
mice were injected three times at weekly intervals.The effects
of these treatments on the growth ofMBT-2 tumorswere then
monitored twice a week. Tumor volume was calculated using
the formula for a rational ellipse: (𝑚
1
× 𝑚
2
× 𝑚
2
× 0.5236),
where 𝑚
1
represents the longer axis and 𝑚
2
represents the
shorter axis. The mice were euthanized when the tumor size
reached >2500mm3 in mean diameter or the mouse was in
poor condition and death was imminent. The significance
of differences in survival was tested by the Kaplan-Meier
analysis (GraphPad Prism 4.0, La Jolla, CA. USA).
2.12. Quantitative RT-PCR. The quantitative RT-PCR pro-
tocol was modified from our previous report [24, 26].
Three days after the last of DNA vaccination, spleen cells
(2 × 106 cells/well) from mice from the different treatment
groups were stimulated with recombinant HER-2/neu pro-
tein (10 𝜇g/mL, R&D Systems) in a 24-well plate for 48 hr.
After stimulation, CD4+ T cells were purified by positive
selection (purity >90%) (Stem Cell Technologies, Grenoble,
France). Then, total RNA was extracted using the RNAspin
Mini Kit (GE Healthcare, Buckinghamshire, UK). cDNA was
generated from denatured total RNA using a Transcriptor
First Strand cDNA Synthesis Kit (Roche) according to the
manufacturer’s instructions. The specific primers were used
as previously described [24, 26] and as described below:
IFN-𝛾, F: 5󸀠-ACTGGCAAAAGGATGGTGAC-3󸀠 and R: 5󸀠-
ACCTGTGGGTTGTTGACCTC-3󸀠; IL-4, F: 5󸀠-TCAACC-
CCCAGCTAGTTGTC-3󸀠 and R: 5󸀠-AAATATHCHAAG-
CACCTTTGG-3󸀠; hypoxanthine guanine phosphoribosyl
transferase 1 (HPRT), F: 5󸀠-GTTGGATAAGGCCAGACT-
TTGTTG-3󸀠 and R: 5󸀠-GATTCAACTTGCGCCATCTTA-
GGC-3󸀠. An Eco Real-Time PCR System (Illumina) and
SYBR Green Master Mix (Roche) were used for quantitative
real-time PCR.The gene expressionwas normalized toHPRT
expression. These normalized values were then expressed
relative to the control group.
2.13. Detection of Antigen-Specific CD8+/IFN-Gamma+ T
Lymphocytes in Spleen Cells. The protocol for detection
of antigen-specific CD8+/IFN-gamma+ T lymphocytes was
modified from our previous report [23, 26]. After the
last DNA vaccination for three days, RBC lysis buffer
(eBioscience)-lysed, single-cell spleen suspensions (2 × 106
cells/well) from mice from the different vaccination groups
were pulsed for 18 hr with a peptide pool composed of
10 𝜇g/mL each of peptide 362–370 (EFAGKKI) (BioBa-
sic, Canada) and peptide 404–412 (EEITGYLYI) (BioBasic,
Canada) of the human HER-2/neu sequence. Brefeldin A
(10 𝜇g/mL) (Sigma St. Louis, MO, USA) was added during
the last 6 hr of culture. After stimulation, the cells were
harvested and surfaced-stained with phycoerythrin- (PE-)
conjugated CD8+ (CLONE 53-6.7) (eBioscience). The cells
were subsequently fixed/permeabilized (Cytofix/Cytoperm
Plus; BD Biosciences) and stained with FITC-conjugated
anti-IFN-gamma (XMG1.2) (eBioscience). The percentage of
CD8+IFN-gamma+ double positive cells among gated CD8+
T cells was measured using a FACSCalibur flow cytometer
(BDBiosciences), and the datawere analyzed usingWINMDI
software (Scripps, La Jolla, CA, USA).TheCD8+ T-cell gating
strategy was as follows: the lymphocyte population of the
spleen cells was gated on low forward scatter (FSC) versus
side scatter (SSC) dot plots, and the FITC-labeled CD8+ cells
were further gated within the lymphocyte gate. Cells that
fulfilled these criteria were acquired (1 × 104).
2.14. Statistical Analysis. All statistical analyses were per-
formed using the GraphPad Prism software package version
4.0. The statistical analyses of cytokine production, surface
marker expression, T-cell proliferation, tumor size, and
percentage of CD8+/IFN-gamma+ T lymphocytes, western
blotting, were performed using one-way ANOVA followed
by Tukey’s post hoc test. For analysis of the mouse survival
rates, the Kaplan-Meier method was used, and statistical
significance was determined by log-rank analysis. Values of
𝑃 < 0.05 were considered to be statistically significant.
3. Result
3.1. WE-CN Can Induce BMDCs Phenotypic Maturation.
Mature DCs are characterized by the synthesis and secretion
of proinflammatory cytokines, and upregulation of sur-
face costimulatory molecules and major histocompatibility
complex molecules with important modulatory functions
in inflammatory responses and adaptive immunity [1–3].
Therefore, in the first series of experiments, we investigated
the effect of water extract of Clitocybe nuda (WE-CN) on the
secretion of the selective proinflammatory cytokines TNF-
alpha and IL-6, the Th1 cytokine IL-12, and the Th2 cytokine
IL-4 in the supernatants of BMDCs by sandwich ELISAs.
BMDCs treated with LPS were used as a positive control. As
shown in Figure 1, incubation of DCs with WE-CN greatly
increased the production of TNF-alpha, IL-6, and IL-12 in a
dose-dependent manner, suggesting that WE-CN enhances
the maturation and immunostimulatory activity of DCs.
The maturation status of BMDCs was also indicated by the
enhanced expression of surface molecules on CD11c+ cells.
As shown in Figure 2, WE-CN (100 𝜇g/mL) stimulation of
BMDCs resulted in significant upregulation of costimulatory
molecules (CD80, CD86, and CD40) and major histocom-
patibility complex molecules (MHC class II and MHC class
I) within 24 hr compared to untreated immature BMDCs.
Therefore, morphological changes take place as well during
the life cycle ofDCs: immatureDCprecursors are often small,
round-shaped cells that turn into larger cells with irregular
shape and many cytoplasmic protrusions (dendrites) as the
cell matures [27]. Thus, we also investigated the effect of
WE-CN on the morphological change by phase contrast
microscope. As shown in Figure 3, the shapes of LPS- and
WE-CN-treated DCs were irregular and havemore dendrites
compared to the PBS-treated cells after 24-hour treatment.
Taken together, these results confirming that WE-CN can
induce DC phenotypic maturation.
3.2. WE-CN Increases the Ability of BMDCs to Stimulate
OVA-Specific T-Cell Proliferation. A critical function of mat-
urate DCs is to promote antigen-specific T-cell proliferation.
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Figure 1: Cytokine production is increased in BMDCs stimulated with WE-CN. Immature BMDCs were stimulated with 100 ng/mL LPS or
various concentrations of WE-CN.The control group was treated with PBS alone. Culture supernatants were collected after 24 hr (or 6 hr for
TNF-alpha), and the levels of cytokine secretion were analyzed by ELISA. The data are presented as the means ± SD of samples from three
wells. ∗𝑃 < 0.05 compared to control. All data are representative of three independent experiments showing similar results.
Therefore, we examined the effect of WE-CN on BMDC-
mediated allogeneic T-cell proliferation in a mixed lym-
phocyte reaction (MLR). As shown in Figure 4, at DC-
to-T cells ratios of 1 : 1 and 1 : 5, WE-CN-treated DCs sig-
nificantly induced more proliferation of naı¨ve allogeneic
T cells than those PBS-treated DCs did. To further com-
pare the stimulatory properties of DC cultured with WE-
CN, we next examined the effect of WE-CN on BMDC-
mediated activation ofOVAantigen-specific T-cell responses.
CN-treated, OVA
257–264 (OVAP1), or OVA323–339 (OVAP2)
peptide-loaded BMDCs were cocultured with their allo-
geneic OVA-specific CD4+ OT-II or CD8+ OT-I T cells,
and T-cell proliferation was measured by [3H] thymidine
incorporation. Our results showed that WE-CN-activated
BMDCs effectively induced enhanced OVA-specific CD4+
(OT-II) and CD8+ (OT-I) T proliferative responses in vitro
(Figure 5). In addition, because IFN-𝛾 is produced by acti-
vatedT cells, the IFN-𝛾 levels in the culture supernatantswere
also measured using ELISA. As shown in Figure 5, WE-CN
treatment also increased the amount of INF-𝛾 produced by
the activated CD4+ and CD8+ T cells. These results revealed
that WE-CN enhances the ability of DCs to induce Ag-
specific T-cell immune responses.
3.3. WE-CN Increases MAPK and NF-𝜅B Pathways Activation
in BMDCs. As previously shown, the activation of MAPKs
and NF-𝜅B plays a crucial role in DC maturation and
response to inflammatory stimuli [28, 29]. To gain additional
insight into the molecular mechanism underlying the effects
ofWE-CN,we sought to study the effect ofWE-CN treatment
on the MAPK and NF-𝜅B pathways in BMDCs. BMDCs
were stimulated withWE-CN, and the levels of MAPK phos-
phorylation were assessed by western blotting. Our results
showed that WE-CN can upregulate the phosphorylation of
the MAPKs ERK, p38, and JNK between 60 and 120min
after treatment, whereas the levels of the nonphosphorylated
proteins were not affected (Figure 6(a)). To further deter-
mine whether WE-CN increases the activation of NF-𝜅B,
nuclear extracts were collected and analyzed for NF-𝜅B
binding activity using an ELISA-based assay. As shown in
Figure 6(b), CN treatment resulted in an increase in the
nuclear translocation of p65 and upregulated NF-𝜅B binding
activity at 3 hr after stimulation. Therefore, these results
suggest that CN induces DC activation, possibly through
activation of theMAPK andNF-𝜅B pathways, which partially
explains the activating effect of WE-CN on DC maturation.
3.4. BMDCs from TLR-4/2-Deficient Mice Do Not Respond
to WE-CN Stimulation. The recognition of certain mush-
room compounds, such as water soluble polysaccharide
proteoglycans and proteins, by TLR-2 and TLR-4 has been
demonstrated in DCs and is required for optimal DC
activation [24, 25, 30, 31]. Therefore, we further assessed
whether TLR-2 and/or TLR-4 receptorswere involved inWE-
CN-induced DC activation. The TLR-4-deficient (C3H/HeJ)
and TLR-2−/− (C57BL/6 background) mouse strains are
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Figure 2: WE-CN upregulates the expression of immunomodulatory cell surface markers on BMDCs. Immature BMDCs were stimulated
with 100 ng/mL LPS or 100 𝜇g/mL WE-CN for 24 hr. The control group was treated with PBS alone. After incubation, the expression of the
surface markers CD40, CD80, CD86, MHC class I, andMHC class II was analyzed by flow cytometry with fluorescently labeled Abs. All data
were gated on CD11c+ cells. The gray-filled area represents staining with an isotype-matched control Ab. (a) The histogram shows data from
one representative experiment of each group. (b) The bar graphs represent the mean ± SD from three independent experiments.
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Figure 3: Morphology of the BMDCs treatment with PBS, LPS, or WE-CN under a light microscopy (×200).
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Figure 4: WE-CN induces the capability of stimulating allogeneic
T-cell response in MLR of BMDCs. T cells were prepared from
the spleens of na¨ıve C57BL/6 mice. Purified T cells were then
cocultured with PBS-, LPS- (100 ng/mL), or WE-CN- (100𝜇g/mL)
treated BMDCs at the indicated ratio of DC : T cells for 96 hr. Cell
proliferation was measured by [3H]-thymidine incorporation for
18 hr.Thedata shown represent themean± SDof samples from three
wells. ∗𝑃 < 0.05 compared to control. All data are representative of
three independent experiments showing similar results.
nonresponsive to LPS and lipoteichoic acid (LTA) due to
a point mutation or knockout of their TLR-4 or TLR-2
receptor genes, respectively [25, 30, 31].We used thesemice to
further characterize the function of TLR-4 or TLR-2 in WE-
CN-mediated DC stimulation. Bone marrow-derived DCs
from C3H/HeJ or TLR-2−/− mice and wild-type C3/HeN or
C57BL/6 mice were prepared and phenotypically analyzed.
As shown in Figure 7(a), LPS and LTA did not induce signifi-
cant IL-12 production in TLR-4-deficient or TLR-2−/−
BMDCs, respectively. In addition, WE-CN stimulated IL-
12 production in a dose-dependent manner in wild-type
DCs as expected; however, IL-12 productionwas dramatically
reduced in BMDCs from both TLR-4-deficient and TLR-2
KOmice. We next examined whether the nonresponsiveness
of DCs from TLR-4 mutant or TLR-2 KO mice to WE-CN-
stimulation is functionally related to their NF-𝜅B activity. As
shown in Figure 7(b), the NF-𝜅B activity of the DCs from
TLR-4 and TLR-2 mutant mice was significantly lower upon
WE-CN treatment compared with wild-type DCs. Taken
together, these results show that WE-CN can induce BMDC
maturation through interaction with TLR-4 and/or TLR-2
molecules.
3.5. WE-CN Enhanced the Antitumor Effect of a HER-2/neu
DNA Vaccine. We have previously demonstrated that an
intramuscular HER-2/neu DNA vaccine has a therapeutic
effect on established p185neu-expressing MBT-2 tumors in
C3H/HeN mice [22, 32, 33]. Using this model, we further
examined whether WE-CN can increase the efficacy of a
HER-2/neu DNA vaccine. As shown in Figure 8(a), immu-
nization with either the control vector alone or control vector
plus 100𝜇g/mL WE-CN did not exert therapeutic effects
on MBT-2 tumor growth, and all mice in these two groups
had to be sacrificed due to the size of their tumors or their
overall health; these mice were expected to have become
moribund by day 35 at the latest. In contrast, when the mice
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Figure 5:WE-CN-treated BMDCs increase T-cell activation in response to the specific antigen OVA. (a) CD8+ T cells and CD4+ T cells were
prepared from the spleens of OT-I and OT-II mice, respectively. Purified T cells were cocultured with PBS-, LPS- (100 ng/mL), or WE-CN-
(100𝜇g/mL) treated DCs pulsed with an OVA peptide at the indicated ratio of DC : T cells for 96 hr. Cell proliferation was quantified by
[3H]-thymidine incorporation for 18 hr. (b) Supernatants were collected from cultures after 4 days, and IFN-𝛾 production was measured by
ELISA. The data shown represent the mean ± SD of samples from three wells. ∗𝑃 < 0.05 compared to control. All data are representative of
three independent experiments showing similar results.
were vaccinated with the HER-2/neu DNA alone or HER-
2/neu DNA plus WE-CN (100 𝜇g), the growth of the tumors
was significantly reduced compared to tumors at earlier time
points. However, injection with HER-2/neu DNA plus WE-
CN markedly prolonged survival compared to the HER-
2/neu DNA alone (Figure 8(b)). These results clearly indicate
the additional benefit of CN on the therapeutic efficacy of the
HER-2/neu DNA vaccine.
3.6. WE-CN Promoted the Th1 Immune Responses Induced by
HER-2/neu DNA Vaccination. Our previous study demon-
strated that Th1-based immune responses, specifically the
generation of cytotoxic CD8+ T cells, represent the pri-
mary immunological mechanism for the suppression of the
implantedMBT-2 tumors inmice [22–24, 26, 32, 33]. In addi-
tion, we have shown that WE-CN-stimulated DCs preferen-
tially release the Th1-dominant cytokine IL-12 (Figure 1) and
facilitate Th1 CD4+ differentiation (Figure 5). Therefore, we
hypothesized that WE-CN promotes Th1 immune responses
that consequently enhance the antitumor immunity resulting
from HER-2/neu DNA vaccination. To test this possibility,
spleen cells collected from mice in the different vaccina-
tion groups were stimulated with recombinant HER-2/neu
protein, and the expression of IFN-𝛾 (Th1) and IL-4 (Th2)
within purifiedCD4+ Tcellswas determined by a qPCRassay.
As shown in Figure 9(a), mice immunized with the HER-
2/neu DNA vaccine-CN combination showed significantly
higher levels of IFN-𝛾 than those immunized with the HER-
2/neu DNA vaccine alone; no significant differences were
observed in IL-4 production. To further examine the HER-
2/neu-specific CD8+ responses in vaccinated mice, we used
flow cytometry to analyze the intracellular expression of
IFN-𝛾 in CD8+ T cells. As shown in Figure 9(b), spleen
cells collected from mice immunized with the HER-2/neu
DNA vaccine/WE-CN combination generated more HER-
2/neu-specific CD8+ IFN-gamma T cells than those of the
mice immunized with the HER-2/neu DNA vaccine alone.
These results suggest that coadministration of theHER-2/neu
vaccine withWE-CNmay elicit stronger HER-2/neu-specific
Th1 responses induced by HER-2/neu DNA vaccination,
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Figure 6: WE-CN induces MAPK phosphorylation and NF-𝜅B binding activity in BMDCs. Immature BMDCs were treated with WE-CN
(100𝜇g/mL), and whole cell lysates or the cytosolic fraction of lysates was collected at the indicated time points. (a) MAPK phosphorylation
levels were analyzed by western blot analysis with anti-ERK, anti-JNK, and anti-p38 MAPK antibodies (against both phosphorylated and
nonphosphorylated forms of the proteins). pErk, pp38, and pJNK 2 levels were normalized with total Erk, p38, and JNK levels and then
compared with the control group arranged as one unit. The data represent the mean ± SD of samples from three independent experiments.
(b) The NF-𝜅B assay was described in Section 2. The NF-𝜅B binding activity is shown as relative OD450 levels. The data represent the mean
± SD of samples from three wells. ∗𝑃 < 0.05 compared to control. The data are representative of three independent experiments showing
similar results.
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Figure 7: WE-CN induces IL-12 expression and NF-𝜅B activity through a TLR-4- and/or TLR-2-dependent signaling pathway. BMDCs
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Figure 8: WE-CN enhances the therapeutic effects of a HER-2/neu DNA vaccine against MBT-2 tumors in C3H/HeN mice. Ten days after
s.c. MBT-2 inoculation, the tumor-bearing mice were vaccinated with the indicated formulas. (a) The tumor volumes were measured at the
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indicates comparisonwith theHER-2/neuDNAvaccine alone group (𝑃 < 0.05).The data are representative of three independent experiments
with similar results.
which could enhance the antitumor efficacy of the HER-
2/neu DNA vaccine.
4. Discussion
Dendritic cells (DCs) are a crucial cell type that acts at
the interface of innate and adaptive immune responses and
has the unique ability to activate naive T cells [1–3]. Potent
modulation of the activation and function of this essential
cell type might have potential efficacy against tumor or
virus infection or represent a candidate adjuvant approach
for application in immunotherapy and vaccination [4]. In
this study, we examined the activity of water extract of
C. nuda (WE-CN) on the immune function of DCs. Our
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Figure 9: WE-CN promotes CD4+Th1 differentiation and increased HER-2/neu-specific functional CD8+ T cells in spleens from vaccinated
mice. (a) CD4+ T cells were purified from the different groups and stimulated with recombinant HER-2/neu protein (10 𝜇g/mL). After 3
days, the expression levels of IFN-𝛾 or IL-4 mRNA were determined by quantitative real-time RT-PCR. The data were normalized to HPRT
expression in each sample, and error bars indicate the mean ± SD of six mice per group assessed from three independent experiments. (b)
The spleen cells from the different vaccinated groups were stimulated with a peptide pool composed of 10 𝜇g/mL each of peptide 362–370
(EFAGKKI) (BioBasic, Canada) and peptide 404–412 (EEITGYLYI) of the HER-2/neu sequence. After stimulation for 18 hr, the percentage
of IFN-gamma-producing CD8+ T cells was determined by flow cytometry. The dot plot shows data from one representative mouse from
each group. The bar graph represents the mean ± SD of five mice from two independent experiments. The symbol ∗ indicates a statistically
significant difference compared to control vector-treated mice (𝑃 < 0.05). The symbol ∗∗ indicates a statistically significant difference
compared to the HER-2/neu DNA vaccine alone group (𝑃 < 0.05).
results show that WE-CN induces DC maturation, based
on the levels of costimulatory molecules and cytokines,
and promotes the activation of allogeneic T cells as the
primary DC function. This study is the first to report that
C. nuda has immunostimulatory activity on immune sys-
tems.
DCs are believed to regulate T-cell-mediated immunity.
In addition, the type of cytokines synthesized and released by
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DCs upon activation is believed to play an important role in
determining the fate choice of naı¨ve CD4+ T cells, which can
be subdivided intoTh1,Th2, andTh17 cells andTreg cells [34].
Specifically, IL-12 is a pivotal cytokine forTh1 differentiation,
whereas IL-4 inhibits Th1 but promotes Th2-type responses
[35]. In the present study, we observed that WE-CN can
significantly increase IL-12 production but does not affect
IL-4 production in BMDCs (Figure 1). In addition, we also
showed that coculture of WE-CN-stimulated OVA peptide-
pulsed BMDCs and OVA-specific T cells can significantly
increase IFN-𝛾 production (Figure 5), which is a major
product of Th1 cells [36]. Thus, these results indicate that
WE-CN-stimulated DCs preferentially promoteTh1 immune
responses. Therefore, C. nuda may be effective in antitumor
or antiviral effects or for the treatment of allergic diseases
(which are Th2-dominant immune responses) by resultant
augmentation of Th1 cells.
Recently, IL-17-producing (Th17) cells have been iden-
tified as a novel class of helper CD4+ T cells [37]. IL-17
plays an important role in host defense against bacterial or
fungal infections [38–41]. In addition, Th17 is also related
to the pathogenesis of many chronic inflammatory diseases
and autoimmune diseases [42, 43]. It has been shown that
transforming growth factor-𝛽 (TGF-𝛽), IL-6, IL-21, and IL-
23 are involved inTh17 differentiation [44, 45].We found that
WE-CN significantly enhances the IL-6 production by DCs,
suggesting that Th17 may be induced by WE-CN. However,
we focused on the adjuvant effect of WE-CN and did not
examine the induction of Th17 in this study.
Our present study showed that active MAPKs (ERK,
p38, and JNK) and NF-𝜅B signaling pathways result in
DC maturation (Figure 6). Because NF-𝜅B binding sites are
found in the promoter regions of various proinflammatory
cytokines, including TNF-alpha, IL-6, and IL-12 [46–48],
and of costimulatory molecules, such as CD40 and CD86
[49, 50], the NF-𝜅B pathway may be involved in WE-CN-
induced DC activation. However, the reported role of the
MAPK signaling pathway in DC maturation is controversial.
p38 mitogen-activated protein kinase is well known to play
an important role in DC maturation [29]. Lin et al. have
shown that the ERK signaling pathway is required for
DC maturation and cytokine production by polysaccharide
purified from Ganoderma lucidum [51]. In contrast, the ERK
pathway has also been shown to lead to differentiation of
tolerogenic DCs [52]. Moreover, a previous study has shown
that ERK and JNK signaling pathways activation in DCs
favors aTh2 response, whereas p38 pathway activation favors
a Th1 response [53–55]. One possible explanation is that
the duration and intensity of MAPK signaling activation
during DC maturation may differ in response to different
stimuli, and different activation patterns ofmultiple signaling
pathways may result in varied consequences. Further studies
using pharmacological inhibitors of the MAPK pathway or
overexpression of small interference RNA and dominant-
negative gene strategies are required to clarify the importance
of the intensity and duration of p38, ERK, and JNK phospho-
rylation in WE-CN-induced DC activation.
Recent data have suggested that stimulation through toll-
like receptors (TLRs) is required for the innate immune
response and optimal DC activation [56]. In the present
study, using BMDCs from TLR-4 and TLR-2 mutant mice,
we found that WE-CN induced DC maturation at least in
part through interaction with TLR-4 and TLR-2 (Figure 7).
The specific components of WE-CN that contribute to the
observed effect onDCs remain unclear. Previous studies have
shown that water-soluble polysaccharides, specifically 𝛽-1,3
glucans with 𝛽-1,6 linked side chains, proteoglycans, and
proteins (such as fungal immunomodulatory protein (FIP)
isolated from a various types of edible mushrooms), display
similar effects onDCs by acting on toll-like receptor-2 and/or
-4 [24, 25, 30, 31, 57, 58]. Therefore, we suggest that the
effects of WE-CN on DC activation may be attributed to the
polysaccharide, proteoglycan, and/or protein content ofWE-
CN; however, all of these possibilities require further study.
We identified CN water extracts as novel ligands for
TLR-4 and TLR-2. Because TLR-4 is one of the major
components of the receptor for LPS and concentrations as
low as 50 pg/mL are sufficient to promote DC activation [59],
the possibility of contamination with the endotoxin LPS in
the CN preparations used in this study required examination.
LAL assays showed endotoxin content of <0.1 ng/mL in
our 1mg/mL CN stock solutions, resulting in a maximum
possible contamination throughout the assays of 0.01 ng/mL
in the 100 𝜇g/mL concentration of WE-CN. Titration experi-
ments with purified LPS (Escherichia coli, serotype O26:B6)
were performed and indicated that DCs under the culture
conditions used in our experiments failed to mature in
response to LPS concentrations of <0.1 ng/mL. (see supple-
mental Figures 1(a) and 1(b) in supplementarymaterial avail-
able online at http://dx.doi.org/10.1155/2013/761454). Further-
more, in blocking experiments for LPS, BMDCs were incu-
bated with 5 𝜇g/mL of the LPS inhibitor polymyxin B prior
to WE-CN stimulation. Polymyxin B did not significantly
affect the CN-induced IL-12 production and upregulation of
CD80 but almost completely inhibited the LPS effect in the
same experiment (supplemental Figure 2). Therefore, these
data suggest that CN water extract causes DC maturation in
part by binding to TLR-4 and/or TLR-2.
Our results showed that WE-CN can activate DCs in
part by interaction with TLR-4/TLR-2 receptors (Figure 7).
However, in addition to DCs, various other types of immune
cells (including macrophages and B lymphocytes) can also
express TLR and respond to TLR ligands [60]. Therefore,
further examination of the direct effects of WE-CN on
the functions of other immune cells, such as B cells and
macrophages, is warranted.
DNA vaccines have been reported to generate high
antigen-specific immunity in animal models for treating
various diseases, including established tumors; however, poor
immunogenicity in large animals and humans is the major
obstacle for the practical use of these vaccines [61–63].
Therefore, the development of novel approaches to increase
the immunogenicity of DNA vaccines and circumvent this
limitation is urgently needed. To this end, combining DNA
vaccination with strong adjuvants is one strategy to enhance
the immunogenicity ofDNAvaccines [64].Our present study
showed for the first time that the addition ofWE-CN (100 𝜇g)
significantly enhanced the antitumor effect of a HER-2/neu
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DNA vaccine on tumor growth, resulting in a higher survival
rate compared to the HER-2 DNA vaccine alone group
(Figure 8). Further studies revealed themechanisms bywhich
WE-CN induces antigen-specific Th1 responses, including
increased functional CD8+ T cell populations in spleen cells
and induction of elevated IFN-gamma mRNA expression
levels compared to the HER-2 DNA vaccine alone group
(Figure 9).Therefore, these data (corresponding to the results
in Figures 1 and 5) suggest that WE-CN-stimulated DCs
preferentially promote Th1 immune responses. Moreover,
although we used HER-2/neu as a model antigen to demon-
strate the adjuvant effects ofWE-CN in this study, we propose
that our results are encouraging for the application of C.
nuda extract to enhance the potency of DNA vaccines or
other immunotherapies for the control of other cancers and
infectious diseases.
In summary, for the first time, we present evidence
demonstrating that water extract ofC. nuda can augment DC
maturation in an in vitro culture system and contains adju-
vant activity for DNA vaccines and therapeutic antitumor
potential in a tumor-bearing mouse model. We suggest that
these data may highlight the nutritional and medical value
of C. nuda and can be used as the basis for further research.
However, additional issues still warrant future investigation.
For example, in this study, because we used a crude water
extract of whole C. nuda concentrate, the identity of the
specific components of the C. nuda extract that contribute to
the observed effect onDCs is unclear.Therefore, further stud-
ies are required to identify the specific active component(s)
that is responsible for the observed effect of WE-CN. In
addition, we employed an in vitro culture model in this study
to determine the effect of WE-CM on BMDC maturation,
but we are aware that an in vivo (oral administration and
feeding) design may be more applicable for defining the
effects of dietary mushrooms as a nutritional intervention.
Thus, further examination of whether the in vitro effects can
be recapitulated in vivo (through oral administration and
feeding) will be very important.
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